Volume : 09, Issue : 10, October – 2022

Title:

95.ROLES OF HEALTHCARE PROVIDERS IN MANAGEMENT OF ANXIETY DISORDER IN PRIMARY CARE

Authors :

Roaa Mansour M Alhutayli., Nora Moneer Alhindi., Abdulwahab Abdulmajid Shah Bahai., Duaa Abdulqadir Zaki., Sama Abdalrazq Othman., Hayaa Abdulqadir Zaki.,Maram Abdullah Almalki., Shaza Mansoor Alhotaily., Bandar Saad Alharthi.,Hawazin Mansour Nafadi.,

Abstract :

Anxiety disorders are common mental health issues that are primarily treated in primary care settings. We did a narrative analysis of potential strategies for managing healthcare in countries with universal primary healthcare. Additionally, we examined the impact of treatment providers on the effectiveness of psychiatric treatment. In April 2022, a systematic search was conducted on databases such as PubMed, Cochrane, PsycINFO, CINAHL, and Scopus. The purpose was to identify controlled studies that focused on evidence-based anxiety treatment in primary care. Only studies published in English since 1995 were included in the search. Psychological interventions for anxiety are efficacious in primary care settings and exhibit more efficacy when administered by a specialist (such as a psychologist or clinical psychologist) as opposed to a non-specialist (such as a general practitioner, nurse, or trainee). Nevertheless, individuals without specialized expertise are capable of delivering efficacious treatment in comparison to receiving no care whatsoever. Prescribers must carefully assess the little information on the effectiveness of pharmacological treatments in primary care.

Cite This Article:

References:

1. Ormel J, VonKorff M, Ustun TB, et al. Common mental disorders and disability across cultures. Results from the WHO Collaborative Study on Psychological Problems in General Health Care. JAMA. 1994;272:1741–1748.
2. The WHO World Mental Health Survey Consortium. Prevalence, severity, and unmet need for Treatment of Mental Disorders in the World Health Organization World Mental Health Surveys. JAMA. 2004;291(21):2581–90.
3. Fehm L, Pelissolo A, Furmark T, Wittchen HU. Size and burden of social phobia in Europe. Eur Neuropsychopharmacol. 2005;15(4):425–34.
4. Wittchen H-U, Hoyer J. Generalized Anxiety Disorder: Nature and Course. J Clin Psychiatry. 2001;62(Suppl 11):15–18.
5. Rickels K, Rynn M. Pharmacotherapy of generalized anxiety disorder. J Clin Psychiatry. 2002;63(suppl 14):9–16.
6. Vermani M, Marcus M, Katzman MA. Rates of detection of mood and anxiety disorders in primary care: a descriptive, cross-sectional study. Prim Care Companion CNS Disord 2011;13(2). http://dx.doi.org/10.4088/PCC.10m01013.
7. American Psychiatric Association, DSM-5 Task Force. Diagnostic and statistical manual of mental disorders: DSM-5. Arlington (VA): American Psychiatric Association; 2013.
8. Wittchen H-U, Kessler RC, Beesdo K, et al. Generalized anxiety and depression in primary care: prevalence, recognition, and management. J Clin Psychiatry 2002;63(Suppl 8):24–34.
9. Simon GE, Von Korff M, Piccinelli M, et al. An international study of the relation between somatic symptoms and depression. N Engl J Med 1999;341:1329–35.
10. Gliatto MF. Generalized anxiety disorder. Am Fam Physician 2000;62(7): 1591–600.
11. Kroenke K, Spitzer RL, Williams JBW, et al. Physical symptoms in primary care: predictors of psychiatric disorders and functional impairment. Arch Fam Med 1994;3:774–9.
12. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th edn. Washington, DC: American Psychiatric Association, 2000.
13. Narayana S, Wong CJ. Office-based screening of common psychiatric conditions. Med Clin North Am 2014;98:959–80.
14. Kroenke K, Spitzer FL, Williams JBW, et al. Anxiety disorders in primary care: prevalence, impairment, comorbidity, and detection. Ann Intern Med 2007;146: 317–25.
15. Prins A, Ouimette P, Kimerling R, et al. The primary care PTSD screen (PCPTSD): development and operating characteristics. Prim Care Psychiatr 2003; 9:9–14.
16. Freedy JR, Steenkamp MM, Magruder KM, et al. Post-traumatic stress disorder screening test performance in civilian primary care. Fam Pract 2010;27: 615–24.
17. Otto MW, Tuby KS, Gould RA, McLean RY, Pollack MH. An effect-size analysis of the relative efficacy and tolerability of serotonin selective reuptake inhibitors for panic disorder. Am J Psychiatry. 2001;158(12):1989–1992.
18. Kapczinski F, Lima MS, Souza JS, Schmitt R. Antidepressants for generalized anxiety disorder. Cochrane Database Syst Rev. 2003;(2):CD003592.
19. Wiseman CN, Gören JL. Does bupropion exacerbate anxiety? Curr Psychiatry Rep. 2012;11(6):E3–E4.
20. Bandelow B, Wiltink J, Alpers GW, et al. Deutsche S3-Leitlinie Behandlung von Angststörungen. www.awmf.org/uploads/tx_szleitlinien/051-028l_S3_ Angstst%C3%B6rungen_2014-05_2.pdf.
21. Weich S, Pearce HL, Croft P, et al. Effect of anxiolytic and hypnotic drug prescriptions on mortality hazards: retrospective cohort study. BMJ. 2014;348:g1996.
22. Furukawa TA, Streiner DL, Young LT. Antidepressant plus benzodiazepine for major depression. Cochrane Database Syst Rev. 2001;(2): CD001026.
23. Hoge EA, Ivkovic A, Fricchione GL. Generalized anxiety disorder: diagnosis and treatment. BMJ. 2012;345:e7500.
24. Depping AM, Komossa K, Kissling W, Leucht S. Second-generation antipsychotics for anxiety disorders. Cochrane Database Syst Rev. 2010;(12):CD008120.
25. Guaiana G, Barbui C, Cipriani A. Hydroxyzine for generalised anxiety disorder. Cochrane Database Syst Rev. 2010;(12):CD006815.
26. National Institute for Health and Care Excellence. Generalised anxiety disorder and panic disorder (with or without agoraphobia) in adults: management in primary, secondary and community care. January 2011. http://www.nice.org.uk/Guidance/CG113. Accessed July 10, 2014.
27. Barlow DH, Farchione TJ, Fairholme CP, et al., editors. Unified Protocol for Transdiagnostic Treatment of Emotional Disorders. New York: Oxford University Press; 2011.
28. Botella C, Gallego MJ, Garcia-Palacios A, et al. An Internet-based self-help treatment for fear of public speaking: A controlled trial. Cyberpsychol Behav Soc Netw. 2010;13(4):407–421.
29. Koszycki D, Talijaard M, Segal Z, et al. A randomized trial of sertraline, self-administered cognitive behavior therapy, and their combination for panic disorder. Psychol Med. 2011;41(2):373–383.